Fabio Petrocca | Profiles RNS

Fabio Petrocca, MD

Assistant Professor

Boston University Chobanian & Avedisian School of Medicine

Medicine

Hematology & Medical Oncology

MD, University of Rome

Websites

	LinkedIn
	BUMC
	Google Scholar
	Research Gate

ORCID : 0000-0002-9115-0295

Diversity, Equity, Inclusion and Accessibility

I am part of a dedicated team of healthcare professionals, researchers, students and staff from different countries and various regions of the U.S. The culture of our Section is defined by the unique perspectives that we each bring with us. As both a large academic medical center and safety-net hospital serving the communities of Boston and its surroundings, our trainees engage in cutting edge research and gain real-world clinical experience by caring for local underserved populations. Our multilingual team is committed to promoting cultural competency, equity and inclusion in science, medicine and healthcare. We strive to maintain a workforce that is as diverse as the communities we serve, and aim to create a safe space for our members to learn, grow and succeed in their life goals. Acknowledging that we all have a role to play, I am dedicated to welcoming and celebrating individuals of all races, ethnicities, social backgrounds, religion, gender, sex, age, ability, sexual orientation, veteran status, and national origin.

Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.

iCite Analysis Copy PMIDs To Clipboard

Abdallah M, Arters F, Patel J, Edwards CV, Lerner A, Petrocca F, Dockerty M, Fuller B, Godfrey A, Staron A, Sanchorawala V, Sloan JM, Bertrand KA, Szalat RE. Febrile Neutropenia in Patients with Duffy-null Associated Neutrophil Counts and Multiple Myeloma or AL amyloidosis. Blood Adv. 2024 Sep 30.View Related Profiles.

Lerner, Adam
Staron, Andrew
Edwards, Camille
Petrocca, Fabio
Sloan, J.
Patel, Jasmine
Bertrand, Kimberly
Dockerty, Margaux
Abdallah, Maya
Szalat, Raphael
Sanchorawala, Vaishali

PMID: 39348709

Lin Y, Raje NS, Berdeja JG, Siegel DS, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Massaro M, Petrocca F, Yeri A, Finney O, Caia A, Yang Z, Martin N, Campbell TB, Rytlewski J, Fuller J, Hege K, Munshi NC, Kochenderfer JN. Idecabtagene vicleucel for relapsed and refractory multiple myeloma: post hoc 18-month follow-up of a phase 1 trial. Nat Med. 2023 Sep; 29(9):2286-2294.View Related Profiles.

Petrocca, Fabio
Munshi, Nikhil C.

PMID: 37592106; PMCID: PMC10504071; DOI: 10.1038/s41591-023-02496-0;

Munshi NC, Anderson LD, Shah N, Madduri D, Berdeja J, Lonial S, Raje N, Lin Y, Siegel D, Oriol A, Moreau P, Yakoub-Agha I, Delforge M, Cavo M, Einsele H, Goldschmidt H, Weisel K, Rambaldi A, Reece D, Petrocca F, Massaro M, Connarn JN, Kaiser S, Patel P, Huang L, Campbell TB, Hege K, San-Miguel J. Idecabtagene Vicleucel in Relapsed and Refractory Multiple Myeloma. N Engl J Med. 2021 02 25; 384(8):705-716.View Related Profiles.

Petrocca, Fabio
Munshi, Nikhil C.

PMID: 33626253

Madduri D, Parekh S, Campbell TB, Neumann F, Petrocca F, Jagannath S. Anti-BCMA CAR T administration in a relapsed and refractory multiple myeloma patient after COVID-19 infection: a case report. J Med Case Rep. 2021 Feb 19; 15(1):90. PMID: 33608053; PMCID: PMC7894235; DOI: 10.1186/s13256-020-02598-0;

Samur MK, Fulciniti M, Aktas Samur A, Bazarbachi AH, Tai YT, Prabhala R, Alonso A, Sperling AS, Campbell T, Petrocca F, Hege K, Kaiser S, Loiseau HA, Anderson KC, Munshi NC. Biallelic loss of BCMA as a resistance mechanism to CAR T cell therapy in a patient with multiple myeloma. Nat Commun. 2021 02 08; 12(1):868.View Related Profiles.

Petrocca, Fabio
Munshi, Nikhil C.

PMID: 33558511; PMCID: PMC7870932; DOI: 10.1038/s41467-021-21177-5;

Raje N, Berdeja J, Lin Y, Siegel D, Jagannath S, Madduri D, Liedtke M, Rosenblatt J, Maus MV, Turka A, Lam LP, Morgan RA, Friedman K, Massaro M, Wang J, Russotti G, Yang Z, Campbell T, Hege K, Petrocca F, Quigley MT, Munshi N, Kochenderfer JN. Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma. N Engl J Med. 2019 05 02; 380(18):1726-1737.View Related Profiles.

Petrocca, Fabio
Munshi, Nikhil C.

PMID: 31042825; PMCID: PMC8202968; DOI: 10.1056/NEJMoa1817226;

Chan S, Sridhar P, Kirchner R, Lock YJ, Herbert Z, Buonamici S, Smith P, Lieberman J, Petrocca F. Basal-A Triple-Negative Breast Cancer Cells Selectively Rely on RNA Splicing for Survival. Mol Cancer Ther. 2017 Dec; 16(12):2849-2861.View Related Profiles.

Petrocca, Fabio
Chan, Stefanie

PMID: 28878028; PMCID: PMC5997774; DOI: 10.1158/1535-7163.MCT-17-0461;

Sridhar P, Petrocca F. Regional Delivery of Chimeric Antigen Receptor (CAR) T-Cells for Cancer Therapy. Cancers (Basel). 2017 Jul 18; 9(7). PMID: 28718815; PMCID: PMC5532628; DOI: 10.3390/cancers9070092;

Witt AE, Lee CW, Lee TI, Azzam DJ, Wang B, Caslini C, Petrocca F, Grosso J, Jones M, Cohick EB, Gropper AB, Wahlestedt C, Richardson AL, Shiekhattar R, Young RA, Ince TA. Identification of a cancer stem cell-specific function for the histone deacetylases, HDAC1 and HDAC7, in breast and ovarian cancer. Oncogene. 2017 Mar 23; 36(12):1707-1720. PMID: 27694895; PMCID: PMC5364039; DOI: 10.1038/onc.2016.337;

De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Hoyos JM, Forzati F, Croce CM, Fusco A. Regulation of microRNA expression by HMGA1 proteins. Oncogene. 2016 11 03; 35(44):5817-5818. PMID: 27399337; DOI: 10.1038/onc.2016.136;

Showing 10 of 31 results. Show More

Visone R, Pallante P, Vecchione A, Cirombella R, Ferracin M, Ferraro A, Volinia S, Coluzzi S, Leone V, Borbone E, Liu CG, Petrocca F, Troncone G, Calin GA, Scarpa A, Colato C, Tallini G, Santoro M, Croce CM, Fusco A. Specific microRNAs are downregulated in human thyroid anaplastic carcinomas. Oncogene. 2016 09 29; 35(39):5214. PMID: 27345412; DOI: 10.1038/onc.2016.139;

Gilboa-Geffen A, Hamar P, Le MT, Wheeler LA, Trifonova R, Petrocca F, Wittrup A, Lieberman J. Gene Knockdown by EpCAM Aptamer-siRNA Chimeras Suppresses Epithelial Breast Cancers and Their Tumor-Initiating Cells. Mol Cancer Ther. 2015 Oct; 14(10):2279-91. PMID: 26264278; DOI: 10.1158/1535-7163.MCT-15-0201-T;

Perdigão-Henriques R, Petrocca F, Altschuler G, Thomas MP, Le MT, Tan SM, Hide W, Lieberman J. miR-200 promotes the mesenchymal to epithelial transition by suppressing multiple members of the Zeb2 and Snail1 transcriptional repressor complexes. Oncogene. 2016 Jan 14; 35(2):158-72. PMID: 25798844; DOI: 10.1038/onc.2015.69;

Petrocca F, Altschuler G, Tan SM, Mendillo ML, Yan H, Jerry DJ, Kung AL, Hide W, Ince TA, Lieberman J. A genome-wide siRNA screen identifies proteasome addiction as a vulnerability of basal-like triple-negative breast cancer cells. Cancer Cell. 2013 Aug 12; 24(2):182-96. PMID: 23948298; PMCID: PMC3773329; DOI: 10.1016/j.ccr.2013.07.008;

Petrocca F, Lieberman J. Promise and challenge of RNA interference-based therapy for cancer. J Clin Oncol. 2011 Feb 20; 29(6):747-54. PMID: 21079135; DOI: 10.1200/JCO.2009.27.6287;

Dykxhoorn DM, Wu Y, Xie H, Yu F, Lal A, Petrocca F, Martinvalet D, Song E, Lim B, Lieberman J. miR-200 enhances mouse breast cancer cell colonization to form distant metastases. PLoS One. 2009; 4(9):e7181. PMID: 19787069; PMCID: PMC2749331; DOI: 10.1371/journal.pone.0007181;

Petrocca F, Lieberman J. Micromanipulating cancer: microRNA-based therapeutics? RNA Biol. 2009 Jul-Aug; 6(3):335-40. PMID: 19535911

De Martino I, Visone R, Fedele M, Petrocca F, Palmieri D, Martinez Hoyos J, Forzati F, Croce CM, Fusco A. Regulation of microRNA expression by HMGA1 proteins. Oncogene. 2009 Mar 19; 28(11):1432-42. PMID: 19169275; DOI: 10.1038/onc.2008.495;

Petrocca F, Lieberman J. Micromanagers of immune cell fate and function. Adv Immunol. 2009; 102:227-44. PMID: 19477322; DOI: 10.1016/S0065-2776(09)01204-8;

Visone R, Petrocca F, Croce CM. Micro-RNAs in gastrointestinal and liver disease. Gastroenterology. 2008 Dec; 135(6):1866-9. PMID: 19013167; DOI: 10.1053/j.gastro.2008.10.074;

Petrocca F, Lieberman J. RIG-ing an antitumor response. Nat Med. 2008 Nov; 14(11):1152-3. PMID: 18989278; DOI: 10.1038/nm1108-1152;

Petrocca F, Vecchione A, Croce CM. Emerging role of miR-106b-25/miR-17-92 clusters in the control of transforming growth factor beta signaling. Cancer Res. 2008 Oct 15; 68(20):8191-4. PMID: 18922889; DOI: 10.1158/0008-5472.CAN-08-1768;

Ambs S, Prueitt RL, Yi M, Hudson RS, Howe TM, Petrocca F, Wallace TA, Liu CG, Volinia S, Calin GA, Yfantis HG, Stephens RM, Croce CM. Genomic profiling of microRNA and messenger RNA reveals deregulated microRNA expression in prostate cancer. Cancer Res. 2008 Aug 1; 68(15):6162-70. PMID: 18676839; PMCID: PMC2597340; DOI: 10.1158/0008-5472.CAN-08-0144;

Petrocca F, Visone R, Onelli MR, Shah MH, Nicoloso MS, de Martino I, Iliopoulos D, Pilozzi E, Liu CG, Negrini M, Cavazzini L, Volinia S, Alder H, Ruco LP, Baldassarre G, Croce CM, Vecchione A. E2F1-regulated microRNAs impair TGFbeta-dependent cell-cycle arrest and apoptosis in gastric cancer. Cancer Cell. 2008 Mar; 13(3):272-86. PMID: 18328430; DOI: 10.1016/j.ccr.2008.02.013;

Iorio MV, Visone R, Di Leva G, Donati V, Petrocca F, Casalini P, Taccioli C, Volinia S, Liu CG, Alder H, Calin GA, Ménard S, Croce CM. MicroRNA signatures in human ovarian cancer. Cancer Res. 2007 Sep 15; 67(18):8699-707. PMID: 17875710

Visone R, Russo L, Pallante P, De Martino I, Ferraro A, Leone V, Borbone E, Petrocca F, Alder H, Croce CM, Fusco A. MicroRNAs (miR)-221 and miR-222, both overexpressed in human thyroid papillary carcinomas, regulate p27Kip1 protein levels and cell cycle. Endocr Relat Cancer. 2007 Sep; 14(3):791-8. PMID: 17914108

Bloomston M, Frankel WL, Petrocca F, Volinia S, Alder H, Hagan JP, Liu CG, Bhatt D, Taccioli C, Croce CM. MicroRNA expression patterns to differentiate pancreatic adenocarcinoma from normal pancreas and chronic pancreatitis. JAMA. 2007 May 2; 297(17):1901-8. PMID: 17473300

Vecchione A, Baldassarre G, Ishii H, Nicoloso MS, Belletti B, Petrocca F, Zanesi N, Fong LY, Battista S, Guarnieri D, Baffa R, Alder H, Farber JL, Donovan PJ, Croce CM. Fez1/Lzts1 absence impairs Cdk1/Cdc25C interaction during mitosis and predisposes mice to cancer development. Cancer Cell. 2007 Mar; 11(3):275-89. PMID: 17349584; PMCID: PMC1987708; DOI: 10.1016/j.ccr.2007.01.014;

Petrocca F, Iliopoulos D, Qin HR, Nicoloso MS, Yendamuri S, Wojcik SE, Shimizu M, Di Leva G, Vecchione A, Trapasso F, Godwin AK, Negrini M, Calin GA, Croce CM. Alterations of the tumor suppressor gene ARLTS1 in ovarian cancer. Cancer Res. 2006 Nov 1; 66(21):10287-91. PMID: 17079447

Volinia S, Calin GA, Liu CG, Ambs S, Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, Prueitt RL, Yanaihara N, Lanza G, Scarpa A, Vecchione A, Negrini M, Harris CC, Croce CM. A microRNA expression signature of human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 2006 Feb 14; 103(7):2257-61. PMID: 16461460; PMCID: PMC1413718; DOI: 10.1073/pnas.0510565103;

This graph shows the total number of publications by year, by first, middle/unknown, or last author.

Bar chart showing 31 publications over 13 distinct years, with a maximum of 5 publications in 2007 and 2008